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Abstract 
Background: Omentin-1, a novel adipocytokine mainly expressed in visceral adipose tissue, has been found to 
inhibit the inflammatory response and improve insulin resistance as well as other obesity-related disorders. This study 
investigated the association between omentin-1 expression in human epicardial adipose tissue (EAT) and coronary 
atherosclerosis.
Methods: Serum samples, and paired biopsies from EAT and subcutaneous adipose tissue (SAT), were obtained from 
patients with and without coronary artery disease (CAD, n = 28 and NCAD, n = 12, respectively) during elective cardiac 
surgery. Coronary angiography was performed to identify CAD presence. Serum omentin-1 and adiponectin levels were 
measured by ELISA. mRNA expression of omentin-1 and adiponectin was detected in adipose tissue by quantitative real-
time PCR, and omentin-1 protein expression was evaluated by immunohistochemistry. Correlation and multivariate linear 
regression analyses were performed to determine the association between omentin-1 expression and clinical risk factors.
Results: mRNA and protein expression of omentin-1 were higher in EAT than paired SAT in patients with CAD and 
NCAD. Compared with NCAD patients, CAD patients had lower omentin-1 and adiponectin mRNA levels in EAT and 
serum levels as well as lower omentin-1 protein levels. Among patients with CAD, omentin-1 expression was lower 
in EAT surrounding coronary segments with stenosis than those without stenosis, in terms of mRNA and protein, 
whereas adiponectin mRNA level in EAT did not seem to differ between stenotic and non-stenotic coronary segments 
in CAD patients. In multivariate linear regression analysis, CAD was an independent predictor of EAT omentin-1 mRNA 
expression (beta = −0.57, 95 % CI −0.89 to −0.24; P = 0.001) and serum omentin-1 levels (beta = −0.35, 95 % CI 
−0.67 to −0.03; P = 0.036).
Conclusions: Circulating and EAT-derived omentin-1 levels were reduced in patients with CAD. Omentin-1 expres-
sion in patients with CAD was lower in EAT adjacent to coronary stenotic segments than non-stenotic segments.
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Background
Obesity is an important risk factor for cardiometabolic 
diseases and its prevalence has risen substantially over 
the last decade [1]. Accumulation of visceral adipose tis-
sue, accompanied by chronic low-grade inflammation, is 
causally linked to the initiation and progression of mul-
tiple obesity-related disorders, including type 2 diabetes 
mellitus (T2DM), dyslipidemia and atherosclerosis [2, 3]. 
Epicardial adipose tissue (EAT) has emerged as a novel 
target for stratification of cardiometabolic risk factors 
due to its distinctive location, and multifaceted meta-
bolic properties with systemic and local effects. Because 
EAT is not separated from adjacent myocardium or 
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the coronary artery vascular wall by fascia, paracrine 
or vasocrine interactions are able to occur [4]. In addi-
tion, EAT is an active endocrine organ that expresses 
and secretes numerous adipocytokines [5, 6]. It has been 
established that the equilibrium between pro-inflamma-
tory and anti-inflammatory adipocytokine production 
by EAT is altered in certain pathological conditions [7, 
8]. In patients with coronary artery disease (CAD), adi-
ponectin mRNA expression was markedly decreased in 
EAT, whereas multiple pro-inflammatory adipocytokines 
mRNA expression, including chemerin, IL-1β, IL-6 and 
TNF-α, were significantly increased [5, 9]. Thus, it is sup-
posed that, adipocytokines secreted by EAT via both 
paracrine and vasocrine mechanisms may regulate the 
process of atherosclerosis [4].
Omentin-1, also known as intelectin-1 [10], is abun-
dantly expressed in human visceral adipose tissue and it 
has been demonstrated to modulate obesity-related car-
diometabolic disorders via anti-inflammatory activity 
[11]. Lower circulating omentin-1 levels associated with 
various metabolic risk factors, including elevated blood 
pressure, increased waist circumstance, dyslipidemia and 
glucose intolerance [12]. In addition, serum omentin-1 
levels were negatively associated with carotid plaque and 
positively correlated with cardiac autonomic neuropathy 
in patients with T2DM [13, 14]. Patients with CAD have 
also been observed to have lower circulating omentin-1 
levels compared with those without CAD [15, 16]. Fur-
thermore, it has been reported that serum omentin lev-
els is a significant predictor of cardiovascular events in 
patients with suspected CAD and heart failure, as well 
as in hemodialysis patients with subclinical atherosclero-
sis [17–19]. Although omentin-1 has been identified as a 
promising biomarker for obesity-related cardiometabolic 
diseases, the association between EAT omentin-1 expres-
sion and coronary atherosclerosis has not been clarified. 
To address this, human omentin-1 mRNA and protein 
expression in EAT was evaluated in patients undergo-




Between July and November 2015, the study enrolled 40 
patients who underwent elective cardiac surgery. Inva-
sive coronary angiography was performed to identify 
CAD, and patients were divided into the CAD (n = 28) or 
non-CAD (NCAD; n =  12) group. CAD group referred 
to patients with three-vessel disease, left main disease or 
two-vessel disease with proximal left anterior descend-
ing lesion indicated for off-pump coronary artery bypass 
grafting (CABG). NCAD group referred to patients 
undergoing open-heart surgery for valvular replacement 
or atrial septal defect repair and no stenosis was found 
in coronary artery lumen. Key exclusion criteria were: 
age >80 years, acute myocardial infarction, active chronic 
inflammation disease, liver or renal failure, and pharma-
cological glucocorticoid or immunosuppressive therapy.
The study protocol complied with the Declaration of 
Helsinki and was approved by the ethics committee of 
Beijing Anzhen Hospital of Capital Medical Univer-
sity. Written informed consent was obtained from each 
patient before enrollment.
Clinical data collection
Clinical characteristics, including demographic data, 
body weight, height, waist circumference, medical his-
tory and medication use, were obtained from the hospital 
records. Body mass index (BMI) was calculated as weight 
(kg) divided by square of height (m2).
Blood sample measurement
After an overnight fast of 12  h, venous blood samples 
were collected in sodium heparin Vacutainers (Bec-
ton–Dickinson), followed by centrifuging for 15  min at 
3000×g, and storage of serum samples at −80  °C. Base-
line levels of fasting glucose, insulin, glycosylated serum 
protein, lipid profiles, creatinine, and high-sensitivity 
C-reactive protein (hsCRP) were measured in the cen-
tral laboratory of Beijing Anzhen Hospital. Homeostasis 
model assessment of insulin resistance (HOMA-IR) was 
used to estimate insulin sensitivity, as calculated by fast-
ing glucose (mmol/L) × fasting insulin (μU/mL)/22.5.
Concentrations of serum omentin-1 (BioVendor, 
Czech Republic) and adiponectin (R&D System, USA) 
were detected by commercially available enzyme-linked 
immunosorbent assay (ELISA) kits following the manu-
facturer’s instructions. ELISA intra-assay and inter-assay 
coefficients of variation were both <5 %. All samples were 
measured in duplicate.
Adipose tissue acquisition
Two portions of adipose biopsy were harvested, includ-
ing EAT near right coronary artery ostium, with or with-
out local coronary stenosis, and subcutaneous adipose 
tissue (SAT) from the area of chest incision. The tissue 
samples (average 0.4  g) were rinsed with phosphate-
buffered saline and then divided into two portions. One 
portion was stored in liquid nitrogen for RNA isolation 
and the other was immersed in neutralized formalin for 
immunohistochemistry.
RNA isolation and quantitative real‑time PCR
Total RNA was extracted from samples using Trizol rea-
gent (Invitrogen, USA). The concentration and purity of 
extracted RNA were assessed by calculating the ratio of 
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optical density at 260 and 280 nm (OD 260/280), and the 
integrity of RNA was reflected by the 18S and 28S riboso-
mal bands. Two µg of RNA from each biopsy was reverse 
transcribed with GoScript Reverse Transcription System 
(Promega, USA) according to the instruction manual. 
Quantitative real-time PCR analysis was conducted using 
the CFX Real-Time PCR Detection System (Bio-Rad, 
USA). Each reaction contained 1 µL of resultant cDNA, 
0.5 µL of each primer (10 µmol/L), 8 µL of sterile water 
and 10 µL of SYBR Premix Ex TaqTM (TAKARA, Japan). 
mRNA amplification was performed as follows: 1 min at 
95 °C, then 44 cycles of 5 s at 95 °C and 30 s at 60 °C, fol-
lowed by 0.5 °C increments every 5 s from 55 to 95 °C.
The primers were designed using Primer Premier 6.0 
software (Premier, Canada), with the sequences as fol-
lows: omentin-1, forward 5′-GACGCCCAGAAAACAG 
CATC-3′, reverse 5′-CGTTGGCTGCTCTCTCGTTA-3′; 
adiponectin, forward 5′-CTCCTCCTCACTTCCATTCT 
G-3′, reverse 5′-TTTCACCGATGTCTCCCTTA-3′; 
β-actin, forward 5′-AGGTCATCACCATTGGCAAT-3′, 
reverse 5′-ACTCGTCATACTCCTGCTTG-3′. Threshold 
cycle (CT) values were obtained and relative gene expres-
sion was calculated using the formula 2−ΔΔ CT with SAT 
fat cell fraction as a reference value.
Immunohistochemistry
The biopsies were embedded in paraffin and cut into 
serial sections, and then deparaffinized and rehydrated in 
descending grades of alcohol, followed by staining with 
hematoxylin and eosin. Selected slides were incubated in 
3 % H2O2 for 15 min, and then blocked with normal goat 
serum for 20  min. After removal of excess serum, sec-
tions were incubated with the primary antibody (Omen-
tin-1, 1:200 dilution; Abcam, USA) at 4  °C overnight in 
a moisture chamber. The sections were then incubated 
with biotinylated secondary antibodies for 20  min fol-
lowed by avidin–biotin reagents for 20 min. Slides were 
incubated with Diaminobenzidine (DAB) and counter-
stained for 1  min with hematoxylin. Light microscope 
observations and digital images were recorded. Positive 
staining for omentin-1 was brown. Expression of omen-
tin-1 was semi-quantified by measuring the integrated 
optical density (IOD) of positively stained tissue via 
Image-Pro plus software 6.0 (Media Cybernetics, USA). 
The IOD of each slide was calculated from four separate 
fields viewed at ×200 magnification.
Statistical analysis
Continuous data with a normal distribution were 
expressed as the mean  ±  SD or the median (lower 
quartile, upper quartile), as appropriate. Mean values 
were compared by the Student’s t test, while median 
values were compared by the Mann–Whitney U test. 
Categorical variables were expressed as percentages and 
analyzed by a Chi square test. Spearman correlation test-
ing was performed between EAT omentin-1 mRNA lev-
els and EAT adiponectin mRNA levels as well as serum 
omentin-1 levels. The associations between EAT mRNA 
omentin-1 levels and serum omentin-1 levels with clini-
cal factors, including CAD and local coronary stenosis, 
were determined by univariate analysis and multivariate 
linear regression analysis. All statistical analyses were 
performed using SPSS 17.0 software (SPSS Inc., Chicago, 
IL, USA). P < 0.05 was considered statistically significant.
Results
Patient characteristics
The baseline characteristics of patients are presented in 
Table 1. Patients with CAD were subdivided into stenosis 
(n = 15) and non-stenosis (n = 13) subgroups, according 
to the presence or absence of local stenosis near right coro-
nary artery ostium. Compared with the NCAD group, the 
CAD group were more likely to be overweight or obese, 
and treated with aspirin, nitrates, statins and β-blockers. 
Compared with the stenosis and non-stenosis subgroups, 
there were no significant differences in age, sex, body 
weight, diabetes, hypertension, current medications and 
laboratory examinations, except for serum creatinine levels.
Quantitative real‑time PCR analysis
Because of inadequate adipose tissue, three EAT and two 
SAT samples were excluded from the CAD group. As 
shown in Fig.  1a, omentin-1 mRNA levels were higher 
in EAT than paired SAT samples in the CAD group (9.86 
vs 0.20, P < 0.001) and the NCAD group (334.21 vs 0.72, 
P  <  0.001). Figure  1b showed that adiponectin mRNA 
levels were lower in EAT than paired SAT samples in 
the CAD group (0.47 ± 0.24 vs 0.81 ± 0.71, P = 0.0287), 
whereas adiponectin mRNA levels did not seem to dif-
fer between EAT and paired SAT samples in the NCAD 
group (1.03 ± 0.63 vs 1.00 ± 0.60, P = 0.89).
EAT omentin-1 and adiponectin mRNA levels 
were markedly decreased in CAD patients compared 
with NCAD patients (Fig.  2a. omentin-1 0.02 vs 0.59, 
P < 0.001; Fig. 2b. adiponectin 0.43 ± 0.22 vs 1.00 ± 0.61, 
P  <  0.001). The stenosis subgroup of CAD patients had 
lower EAT omentin-1 expression than the non-stenosis 
subgroup (0.01 vs 0.14, P =  0.0127), while non-stenosis 
CAD patients had lower EAT omentin-1 expression than 
NCAD patients (0.14 vs 0.59, P = 0.0392). There seemed 
no significant difference between stenosis and non-
stenosis subgroups of CAD patients on EAT adiponec-
tin expression (0.37 ± 0.20 vs 0.51 ± 0.23, P = 0.1005), 
while non-stenosis CAD patients had lower EAT adi-
ponectin expression than NCAD patients (0.51 ± 0.23 vs 
1.00 ± 0.61, P = 0.0221).
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Immunohistochemical analysis
EAT and paired SAT specimens were randomly selected 
from the CAD group (stenosis subgroup, n  =  9; non-
stenosis subgroup, n = 9) and the NCAD group (n = 9), 
respectively. Figure  3A shows representative immuno-
stained adipose sections from patients in the CAD group 
(Fig. 3A-a, b, c) and the NCAD group (Fig. 3A-d, e). In all 
patients, omentin-1 was highly expressed in EAT, most 
prominently in stromal vascular cells, but was barely 
detectable in SAT. As shown in Fig. 3B, omentin-1 pro-
tein levels were higher in EAT than paired SAT in both 
the CAD group (49,053  ±  22,145 vs 28,340  ±  11,314, 
P  =  0.0032) and NCAD group (91,290  ±  27,006 vs 
27,333  ±  11,648, P  <  0.001). Furthermore, as shown in 
Fig.  3C, omentin-1 protein levels in EAT were lower in 
CAD patients than NCAD patients (49,053  ±  22,145 
Table 1 Baseline characteristics of patients in the CAD vs NCAD groups, and the stenosis vs non-stenosis subgroups
Data are shown as mean ± SD, median (lower quartile, upper quartile), or number (%)
CAD coronary artery disease, NCAD non-coronary artery disease, BMI body mass index, LVEF left ventricular ejection fraction, HOMA-IR homeostasis model assessment 
of insulin resistance, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein, BNP brain 
natriuretic peptide, cTnI cardiac troponin I, T2DM type 2 diabetes, ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin II type 1 receptor blocker
* P < 0.05, CAD group vs NCAD group
§ P < 0.05, non-stenosis subgroup vs NCAD group
# P < 0.05, stenosis subgroup vs non-stenosis subgroup
CAD NCAD (12)
Stenosis (15) Non‑Stenosis (13) Total (28)
Clinical characteristics
 Age (years) 61.73 ± 4.28 60.08 ± 3.80 60.96 ± 4.08 58.50 ± 5.27
 Male (%) 8 (53.3) 10 (76.9) 18 (64.3) 5 (47.1)
 BMI (kg/m2) 25.48 ± 3.91 25.93 ± 2.82 25.69 ± 3.39 23.09 ± 2.32*§
 Waist circumference (cm) 90.11 ± 9.68 94.15 ± 13.31 91.99 ± 11.47 81.05 ± 8.94*§
 Hypertension (%) 4 (26.7) 3 (23.1) 7 (25.0) 1 (8.3)
 T2DM (%) 8 (53.3) 8 (61.5) 16 (57.1) 3 (25.0)
 Smoking (%) 9 (60.0) 9 (69.2) 18 (64.3) 4 (33.3)
 LVEF (%) 57.73 ± 10.31 55.92 ± 9.51 56.89 ± 9.80 56.58 ± 7.50
Laboratory examinations
 Fasting glucose (mmol/L) 5.35 (4.98, 7.30) 5.37 (5.02, 5.65) 5.36 (5.00, 6.30) 5.28 (4.77, 6.04)
 Glycosylated serum protein (%) 15.00 (14.20, 16.80) 14.50 (13.80, 17.20) 14.65 (13.88, 17.03) 14.55 (14.05, 17.75)
 Fasting insulin(μU/ml) 73.10 (13.40, 104.50) 9.80 (6.05, 47.70) 16.35 (7.98, 80.88) 22.30 (11.03, 26.20)
 HOMA-IR 2.49 (1.57, 6.71) 17.38 (3.82, 27.92) 4.28 (2.07, 25.75) 4.27 (2.40, 8.09)§
 Triglycerides (mmol/L) 1.32 (0.91, 2.04) 1.71 (1.15, 2.50) 1.52 (1.02, 2.22) 1.46 (1.07, 2.59)
 Total cholesterol (mmol/L) 4.25 ± 1.27 4.36 ± 0.88 4.30 ± 1.09 4.87 ± 1.32
 HDL-C (mmol/L) 0.96 (0.82, 1.18) 0.81 (0.73, 1.06) 0.88 (0.77, 1.17) 1.18 (0.89, 1.73)
 LDL-C (mmol/L) 2.74 ± 1.31 2.67 ± 0.93 2.70 ± 1.13 3.34 ± 0.84
 Serum creatinine (μmol/L) 74.60 (65.50, 83.10) 82.10 (76.15, 93.95)# 78.70 (66.98, 86.60) 79.90 (65.03, 84.13)
 Homocysteine (μmol/L) 15.50 (11.00, 21.90) 14.20 (11.40, 22.90) 14.35 (11.05, 21.90) 14.45 (10.93, 20.08)
 hsCRP (mg/L) 1.02 (0.38, 3.85) 1.01 (0.74, 2.28) 1.02 (0.57, 3.00) 2.35 (0.67, 5.09)
 BNP (pg/ml) 89.00 (43.00, 164.00) 85.00 (30.50, 169.50) 87.00 (43.00, 157.75) 165.5 (87.75, 252.25)
 cTnI (μg/L) 0.01 (0, 0.02) 0.01 (0, 0.015) 0.01 (0, 0.02) –
Medications
 Aspirin (%) 6 (40.0) 8 (61.5) 14 (50.0) 0 (0)*§
 Nitrates (%) 13 (86.7) 13 (100) 26 (92.9) 2 (16.7)*§
 ACEI/ARB (%) 2 (13.3) 2 (15.4) 4 (14.3) 1 (8.3)
 Statins (%) 9 (60.0) 6 (46.2) 15 (53.6) 0 (0)*§
 β-blockers (%) 9 (60.0) 11 (84.6) 20 (71.4) 0 (0)*§
 Calcium channel blockers (%) 3 (20.0) 4 (30.8) 7 (25.0) 0 (0)
 Insulin (%) 2 (13.3) 2 (15.4) 4 (14.3) 1 (8.3)
 Oral hypoglycemic agents (%) 3 (20.0) 2 (15.4) 5 (17.9) 1 (8.3)
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vs 91,290  ±  27,006, P  <  0.001), while omentin-1 pro-
tein expression in EAT was lower in the stenosis sub-
group than the non-stenosis subgroup (36,845 ± 12,529 
vs 61,262  ±  23,447, P  =  0.0141). In addition, EAT-
derived omentin-1 protein was lower in the non-steno-
sis subgroup than the NCAD group (61,262 ± 23,447 vs 
91,290 ± 27,006, P = 0.0228).
Association of omentin‑1 with coronary atherosclerosis 
and other clinical parameters
Table 2 showed that in univariate analysis, EAT-derived 
omentin-1 mRNA was negatively associated with waist 
circumference (beta = −0.45, 95 % CI −0.73 to −0.14), 
diabetes (beta  =  −0.36, 95  % CI −0.68 to −0.04) and 
CAD (beta  =  −0.66, 95  % CI −0.90 to −0.40). Multi-
variate linear regression analysis, including age, sex, 
waist circumference, diabetes and CAD as covariates, 
demonstrated that the presence of CAD was indepen-
dently associated with EAT omentin-1 mRNA lev-
els (beta = −0.57, 95 % CI −0.89 to −0.24; P = 0.001). 
Among patients with CAD, univariate analysis revealed 
a negative association between EAT-derived omentin-1 
mRNA and local coronary stenosis (beta = −0.44, 95 % 
CI −0.83 to −0.05; P =  0.028). EAT omentin-1 mRNA 
expression was positively associated with that of adi-
ponectin (r = 0.39, P = 0.018), but not with serum omen-
tin-1 levels (r = 0.31, P = 0.062).
Omentin-1 levels in serum were lower in the CAD 
group than the NCAD group (373.71 vs 659.39  ng/mL, 
P  <  0.001). As shown in Table  2, in univariate analy-
sis, serum omentin-1 levels were negatively associated 
with waist circumference (beta = −0.36, 95  % CI −0.66 
to −0.05), HOMA-IR (beta  =  −0.32, 95  % CI −0.64 to 
−0.01), hypertension (beta  =  −0.32, 95  % CI −0.63 to 
−0.01) and CAD (beta = −0.59, 95 % CI −0.86 to −0.33). 
A multivariate linear regression analysis model, including 
age, sex, waist circumference, HOMO-IR, hypertension, 
triglycerides and CAD, demonstrated that the presence of 
CAD was independently associated with serum omenitn-1 

























Fig. 1 Quantitative real-time PCR analysis for adipokines in human adipose tissue. Relative omentin-1 (a) and adiponectin (b) mRNA levels in paired 
EAT and SAT (reference) of the two groups (CAD group, n = 23; NCAD group, n = 12). *P < 0.05, **P < 0.01. CAD coronary artery disease, EAT epicar-




























Fig. 2 Quantitative real-time PCR analysis for adipokines in human adipose tissue. Relative omentin-1 (a) and adiponectin (b) mRNA levels in EAT of 
CAD group (total, n = 25; stenosis subgroup, n = 14; non-stenosis subgroup, n = 11) and NCAD group (reference, n = 12). *P < 0.05, **P < 0.01. CAD 
coronary artery disease, EAT epicardial adipose tissue, NS no significant difference, SAT subcutaneous adipose tissue
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Adiponectin levels in serum were lower in the 
CAD group than the NCAD group (4.57  ±  0.99 vs 
6.98  ±  1.11  ng/mL, P  <  0.001). As shown in Table  3, 
multivariate linear regression analysis indicated that the 
presence of CAD was independently associated with 
EAT adiponectin mRNA levels (beta = −0.49, 95  % CI 
−0.81 to −0.14; P = 0.006) and serum adiopnectin levels 
(beta = −0.82, 95 % CI −0.99 to −0.66; P < 0.001).
Discussion
In this study, we found that in patients with CAD, serum 
and EAT omentin-1 levels were markedly lower than 
in patients without CAD, and this inverse association 
remained after adjusting for well-known risk factors. 
Furthermore, patients with CAD had lower omentin-1 
expression in EAT surrounding stenotic coronary seg-
































Fig. 3 Immunohistochemical analysis for omentin-1 in human adipose tissue. A representative slides of adipose tissue from patients in the CAD 
group (Fig. 3A-a, EAT of non-stenosis subgroup; 3A-b, EAT of stenosis subgroup; 3A-c, SAT) and the NCAD group (Fig. 3A-d, EAT; 3A-e, SAT) (magni-
fied ×200). B results of quantitative immunohistochemical analysis for omentin-1 in EAT and SAT of the two groups (CAD group, n = 9; NCAD 
group, n = 9). C results of quantitative immunohistochemical analysis for omentin-1 in EAT of CAD group (total, n = 18; stenosis subgroup, n = 9; 
non- stenosis subgroup, n = 9) and NCAD group (n = 9). *P < 0.05, **P < 0.01. CAD coronary artery disease, EAT epicardial adipose tissue, SAT subcu-
taneous adipose tissue, IOD integrated optical density
Table 2 Association between EAT as well as serum levels of omentin-1 and variables using univariate analysis and multi-
variate linear regression analysis
Multivariate linear regression model includes age, sex and other variables with P < 0.05 in univariate analysis
EAT epicardial adipose tissue, CI confidence interval, WC waist circumference, CAD coronary artery disease, TC triglycerides, HTN hypertension, T2DM type 2 diabetes, 
HOMA-IR homeostasis model assessment of insulin resistance
Variables EAT mRNA levels Serum levels
Univariate Multivariate  
(R2 = 0.419, P < 0.001)
Univariate Multivariate  
(R2 = 0.246, P = 0.029)
Beta 95 % CI P value Beta 95 % CI P value Beta 95 % CI P value Beta 95 % CI P value
Age 0.01 −0.33 to 0.35 0.946 0.10 −0.19 to 0.39 0.492 −0.27 −0.58 to 0.05 0.095 −0.23 −0.53 to 0.07 0.132
Sex 0.27 −0.06 to 0.60 0.102 0.10 −0.17 to 0.37 0.463 0.30 −0.01 to 0.61 0.060 0.15 −0.12 to 0.42 0.272
WC −0.45 −0.73 to −0.14 0.005 −0.12 −0.42 to 0.19 0.445 −0.36 −0.66 to −0.05 0.024 −0.16 −0.47 to 0.15 0.308
CAD −0.66 −0.90 to −0.40 <0.001 −0.57 −0.89 to −0.24 0.001 −0.59 −0.86 to −0.33 <0.001 −0.35 −0.67 to −0.03 0.036
T2DM −0.36 −0.68 to −0.04 0.029 −0.11 −0.39 to 0.17 0.438 −0.29 −0.60 to 0.03 0.072
TC −0.11 −0.24 to 0.47 0.520 0.36 0.05 to 0.66 0.024 0.23 −0.04 to 0.50 0.093
HTN −0.26 −0.57 to 0.07 0.127 −0.32 −0.63 to −0.01 0.046 −0.02 −0.35 to −0.31 0.887
HOMA-IR −0.21 −0.53 to 0.12 0.210 −0.32 −0.64 to −0.01 0.041 −0.15 −0.48 to 0.17 0.350
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Watanabe and co-workers using immunohistochemistry 
showed that patients with CAD had substantially lower 
omentin-1 expression in EAT and coronary endothe-
lium [20]. However, the baseline characteristics of CAD 
and NCAD patients in Watanabe’s study were not well 
matched. Our present study complements and extends 
prior findings by revealing that omentin-1 expression in 
EAT of CAD patients was significantly lower on both the 
mRNA and protein levels, and these inverse associations 
between CAD and EAT omentin-1 mRNA as well as pro-
tein expression remained after adjusting for well-known 
risk factors. These findings suggest that omentin-1 
derived from EAT associates with CAD, or in another 
way, the entirely coronary atherosclerosis.
However, whether EAT omentin-1 expression associ-
ated with local coronary atherosclerosis has not been 
clarified. Recent researches indicate that EAT or perivas-
cular adipose tissue has crucial roles in the maintenance 
of cardiovascular homeostasis and remodeling under 
physiological or pathological circumstances [21]. It has 
been established that EAT is a source of adipocytokines, 
and is closely linked to the initiation and progression 
of atherosclerosis [4, 5]. More recently, Benedicte et  al. 
identified 400 common genes involved in extracellular 
matrix remodeling, thrombosis and inflammation, which 
were expressed in EAT from the periatrial region, perive-
ntricular area and surrounding the pericoronary artery. 
The authors also showed that omentin was the most 
highly upregulated gene in EAT compared with SAT [22]. 
Similarly, we found that omentin-1 mRNA and protein 
levels were significantly higher in EAT than SAT, regard-
less of pre-existing CAD. Considering the contiguous 
anatomic location and microcirculatory connection, it is 
reasonable to speculate that tissue-specific expression of 
omentin-1 in EAT closely relates to local coronary ath-
erosclerosis via paracrine and vasocrine mechanisms.
To examined the association between adipocytokine 
expression in EAT and local coronary atherosclerosis, 
Verhagen et al. obtained perivascular adipose tissue near 
to stenotic and non-stenotic coronary artery segments 
from the same CAD patient undergoing CABG, and he 
revealed a negative relationship between EAT-derived 
adipocytokine production and local coronary atheroscle-
rosis [23]. Likewise, we found that among patients with 
CAD, omentin-1 mRNA and protein levels in EAT sur-
rounding coronary artery stenotic segments were mark-
edly decreased. There was a negative association between 
EAT-derived omentin-1 mRNA and local coronary ste-
nosis among patients with CAD in a univariate analysis. 
Therefore, we presume that omentin-1 mRNA expres-
sion in EAT was inversely associated with entirely and 
local coronary atherosclerosis. The former association 
was further investigated in the comparison of the non-
stenosis CAD patients and NCAD patients showing that 
omentin-1 mRNA and protein levels were lower in the 
non-stenosis subgroup, which indicated that the negative 
association between omentin-1 expression in EAT and 
CAD is independent of local coronary atherosclerosis.
Generally, explanation of the association between EAT 
derived adipocytokines and coronary atherosclerosis is 
oversimplified and paracrine effects of EAT may be over-
estimated. In fact, the delicate equilibrium between pro-
inflammatory and anti-inflammatory adipocytokines is 
complicated and susceptible to disruption in pathological 
conditions [7]. Adiponectin, positively associated with 
omentin-1 in EAT mRNA expression in our study, was 
Table 3 Association between EAT as well as serum levels of adiponectin and variables using univariate analysis and mul-
tivariate linear regression analysis
Multivariate linear regression model includes age, sex and other variables with P < 0.05 in univariate analysis
EAT epicardial adipose tissue, CI confidence interval, BMI body mass index, CAD coronary artery disease, HOMA-IR homeostasis model assessment of insulin resistance, 
HTN hypertension, TC triglycerides
Variables EAT mRNA levels Serum levels
Univariate Multivariate  
(R2 = 0.246, P = 0.01)
Univariate Multivariate  
(R2 = 0.799, P < 0.001)
Beta 95 % CI P value Beta 95 % CI P value Beta 95 % CI P value Beta 95 % CI P value
Age −0.20 −0.53 to 0.13 0.231 −0.09 −0.39 to 0.22 0.557 −0.25 −0.57 to 0.07 0.117 0.02 −0.13 to 0.18 0.767
Sex 0.16 −0.18 to 0.50 0.338 0.05 −0.26 to 0.35 0.770 0.05 −0.28 to 0.38 0.752 −0.07 −0.22 to 0.08 0.351
BMI −0.32 −0.65 to 0.001 0.050 −0.10 −0.43 to 0.23 0.526 −0.23 −0.55 to −0.09 0.151 −0.18 −0.35 to −0.01 0.035
CAD −0.56 −0.83 to −0.27 <0.001 −0.49 −0.81 to −0.14 0.006 −0.74 −0.96 to −0.52 <0.001 −0.82 −0.99 to −0.66 <0.001
TC −0.03 −0.39 to 0.33 0.861 −0.32 −0.63 to −0.01 0.044 −0.57 −0.73 to −0.41 <0.001
HOMA-IR -0.24 −0.24 −0.56 to 0.09 0.148 −0.23 −0.55 to 0.10 0.163
HTN −0.26 −0.58 to 0.07 0.117 −0.09 −0.42 to 0.24 0.578
Glucose −0.18 −0.50 to 0.16 0.293 0.03 −0.30 to 0.36 0.856
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found to be lower in patients with CAD on EAT mRNA 
levels and serum levels [5, 24], moreover, we observed 
that this reverse association between EAT mRNA lev-
els as well as serum levels of adiponectin and CAD still 
existed adjusting for traditional risk factors. However, 
adiponectin mRNA expression was not expectantly sig-
nificantly lower in EAT near to stenotic segments com-
pared with non- stenotic segments in both Verhagen’s 
study and this study. In another small-scale study, adi-
ponectin mRNA levels were not significantly lower in 
EAT near to coronary segments containing a bare metal 
stent with heavier atherosclerotic burden when com-
pared with EAT adjacent to segments without a stent 
[25]. Moreover, secretion of pro-inflammatory adipo-
cytokines (IL-1α, IL-17, IL-18 and IL-23) from EAT 
adjacent to coronary stenotic segments was markedly 
reduced in Verhagen’s study [23]. Overall, patients with 
CAD have a stronger pro-inflammatory profile of adi-
pocytokines in EAT than NCAD patients [26], whereas 
the regulation of adipocytokines in EAT derived from 
coronary stenotic segments of advanced CAD patients 
appears to be sophisticated.
Omentin-1 is secreted by visceral fat, and its local con-
centration in visceral fat may greatly exceed that in the 
circulation or SAT [27]. In this study, EAT omentin-1 
mRNA expression was not positively associated with 
serum omentin-1 levels. Meanwhile, because omentin-1 
circulates in blood, it may improve insulin sensitivity 
and glucose metabolism in the entire body, which would 
have an impact on the initiation and progression of obe-
sity-related disorders such as CAD. In the present study, 
omentin-1 levels in serum were negatively associated with 
the presence of CAD, even after adjusting for traditional 
risk factors. This relationship was confirmed in a meta-
analysis demonstrating that serum omentin-1 levels were 
independently and negatively associated with CAD [28]. 
The present study also showed that serum omentin-1 
was negatively correlated with waist circumference and 
HOMA-IR. These results are in agreement with findings 
that serum omentin-1 levels are increased in most obesity 
following bariatric surgery with lower cardiovascular risk 
[29] and in diabetes after treatment of pioglitazone with 
improved cardiac diastolic function [30].
The in vivo effect of omentin-1 halted the development 
of atherosclerosis has been investigated in apolipoprotein 
E-deficient (Apoe−/−) mice with decreased macrophage 
infiltration and pro-inflammatory genes expression 
[20, 31]. In vitro, omentin-1 promoted differentiation 
of macrophages into the anti-inflammatory M2 pheno-
type, and suppressed inflammatory responses and foam 
cell formation [20]. Omentin-1 has been demonstrated 
to promote vasodilation and survival of endothelial cells 
through activation of AMPK/eNOS pathways [32], and to 
alleviate inflammation in endothelial cells via inhibition 
of TNF-α pathways [33]. In addition, omentin-1 inhibited 
monocyte adhesion to smooth muscle cells by reduc-
ing VCAM-1 expression through inhibition of p38/JNK 
signaling [34]. Furthermore, omentin-1 was observed to 
increase in macrophage-derived foam cells and medial 
layer VSMCs within advanced coronary plaques and the 
circulating blood in patients with acute coronary syn-
drome (ACS) [20], this implies that omentin-1 may exert 
cardio-protective effects in the acute-phase of ACS, 
which is of significant importance for targeted therapy.
The limitations of this study should be noted. The char-
acteristics of patients in the CAD and NCAD groups 
were not balanced, which may confound the association 
between omentin-1 expression and CAD. Although mul-
tivariate regression analysis was performed, the existence 
of residual confounding variables cannot be excluded. 
Because of the small sample size, it was not possible to 
investigate the inverse association between EAT omen-
tin-1 levels and local coronary atherosclerosis in CAD 
patients by multivariate linear regression analysis. This 
was a cross-sectional and observational study, therefore, 
the results should be considered exploratory and hypoth-
esis generating. Conclusions concerning the mechanism 
and causality between omentin-1 and coronary athero-
sclerosis cannot be made. Further studies are required 
to evaluate whether EAT-derived omentin-1 has a direct 
effect on coronary atherosclerosis.
Conclusions
This study established that EAT and serum omentin-1 
levels were negatively associated with the presence of 
CAD. However, the inverse relationship between EAT 
omentin-1 levels and local coronary atherosclerosis 
requires further elucidation. Future studies focusing on 
the causality between EAT omentin-1 expression and 
coronary atherosclerosis as well as its underlying mecha-
nisms are warranted.
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